Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
IMImpel Pharmaceuticals Inc. logo

Impel Pharmaceuticals Inc. (IMPL)

NASDAQ Global Market · Currency in USD
$0.04 ▼ -0.02 (-27.27%)
At close: Dec 20, 3:58 PM ET. Market closed.

Summary

Previous Close
$0.06
Open
$0.05
Day's Range
$0.02 – $0.05
52 Week Range
$0.02 – $4.20
Volume
720,030
Avg. Volume
1,048,481
Market Cap
$956.00K
Beta (5Y Monthly)
1.17
PE Ratio (TTM)
--
EPS (TTM)
-$5.52
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Impel Pharmaceuticals Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
160
CEO
Leonard S. Paolillo

Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder.

Earnings

DateEst.Actual
Nov 14, 2023-$0.36-$0.58Miss
Aug 18, 2023-$0.65-$0.31Beat
May 12, 2023-$0.90-$1.27Miss
Mar 24, 2023-$1.04-$0.97Beat
Nov 14, 2022-$0.87-$1.31Miss
Aug 15, 2022-$1.13-$1.09Beat

Analyst view

Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on IMPL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.